ERBB2 and gastric cancer: In summary, with longer follow-up time, this updated Q-TWiST analysis demonstrated significant improvement in quality-adjusted survival with nivolumab plus chemotherapy versus chemotherapy in patients with previously untreated advanced, non-HER2-positive GC/GEJC/EAC, confirming the clearly clinically important benefit of this treatment.